# Kaasim Mahmood

> Kaasim Mahmood is a Series A investor at Advent Life Sciences backing Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advent Life Sciences](https://shizune.co/investors/profile/advent-life)
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Aug 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kaasim-mahmood-339818/

Kaasim Mahmood is a Series A investor at Advent Life Sciences in London focused on Health Care and Biotechnology. Kaasim joined Advent in June 2005 after spending four years at Cutfield Freeman & Co, a London based corporate finance boutique, where he worked on a wide variety of transactions including financings, mergers and acquisitions.Kaasim is qualified as a medical doctor and has an MB BS from the Royal Free & University College MedicalSchool, London.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Electronics | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyted | Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather thantreated. | $44M | Series B | Aug 30, 2025 |  |
| CN Creative | Headquartered in the Bioscience Incubator at Manchester University in the UK, CN Creative provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. It has developed a distinctive portfolio of products and services focused on smoking cessation and harm reduction, including user-friendlynicotine delivery systems and patient-focused smoking cessation and support services. CNC's diverse products include QuitDirect, an NHS-accredited supplier of comprehensive smoking cessation services, the Intellicig® electronic cigarette, ECOpure proprietary high purity nicotine preparations and NRT Direct, which provides traditional nicotine replacement therapy products and patient support services to publicly and privately sponsored smoking cessation programmes. CNC's Nicadex(TM) electronic inhaler nicotine replacement therapy product is in clinical development for use as part of medically supervised smoking cessation programmes. | $2.6M | Series A | Jan 26, 2012 |  |

2 of 2 investments shown.

## Co-investors
- [BGF Ventures](https://shizune.co/investors/profile/bgf-ventures) — VC Fund, 1 deal together
- [British Business Bank](https://shizune.co/investors/profile/british-business-bank) — VC Fund, 1 deal together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 1 deal together
- [Morningside](https://shizune.co/investors/profile/morningside-group) — VC Fund, 1 deal together

## About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

5 contacts available at Advent Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew J Wood | Venture Partner | https://shizune.co/investors/profile/andrew-j-wood |
| Dale Pfost | General Partner | https://shizune.co/investors/profile/dale-pfost |
| Kaasim Mahmood | General Partner | https://shizune.co/investors/profile/kaasim-mahmood |
| Satish Jindal | General Partner | https://shizune.co/investors/profile/satish-jindal |
| Shahzad Malik | General Partner | https://shizune.co/investors/profile/shahzad-malik |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kaasim Mahmood invest in?

Kaasim Mahmood invests primarily in Health Care, Biotechnology and Electronics startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kaasim Mahmood last invest?

The most recent investment recorded for Kaasim Mahmood closed in Aug 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co